MWN-109 is a synthetic peptide in Phase 2 since August 2025, with a concurrent Phase 1b MAD study
In a small number of cases, dizziness may indicate an underlying issue requiring clinical assessment
In many cases, individuals with B12 deficiency may receive injections once a week for several weeks, followed by less frequent maintenance injections, such as once a month
Healthcare providers should obtain a thorough medical history, including previous pancreatic events, and document the risk-benefit discussion with patients
However, researchers note that consistency is a major hurdle, with more than half of users discontinuing the medication within two years, often restarting later
HDRS-17, 17-item Hamilton Depression-Rating Scale